A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding

American Journal of Obstetrics and Gynecology
Ellen W FreemanTammie L Adomako


We sought to assess the efficacy and safety of 2 dosing regimens of a novel, oral tranexamic acid formulation (Lysteda; Ferring Pharmaceuticals Inc, Parsippany, NJ) in women with cyclic heavy menstrual bleeding. This was a multicenter, double-blind, placebo-controlled, randomized, parallel-group trial for 3 menstrual cycles (n = 304). Women with mean menstrual blood loss (MBL) of ≥ 80 mL/cycle were randomized to receive either 1.95 g/d or 3.9 g/d of tranexamic acid or placebo for up to 5 days of menstrual bleeding. Primary efficacy endpoints were mean MBL reduction from baseline, mean MBL reductions that were considered "meaningful" by subjects, and mean MBL reductions from baseline > 50 mL/cycle. Adverse events (AEs) were also assessed. Only the 3.9 g/d group met all 3 primary efficacy endpoints. AEs did not significantly differ among the 3 groups. There were no serious study-related AEs. The 3.9-g/d dose met all 3 primary efficacy endpoints, whereas the 1.95 g/d dose met 2 primary efficacy endpoints. Both doses were well tolerated.

Associated Clinical Trials


Apr 1, 1987·European Journal of Obstetrics, Gynecology, and Reproductive Biology·C J DockerayJ Bonnar
May 1, 1995·British Journal of Obstetrics and Gynaecology·J T PrestonS K Smith
Jul 5, 2001·Fertility and Sterility·K M WyattP M O'Brien
Jan 15, 2002·European Journal of Obstetrics, Gynecology, and Reproductive Biology·U H Winkler
Mar 8, 2003·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·M ShapleyP R Croft
Jun 27, 2003·Drugs·Keri Wellington, Antona J Wagstaff
May 30, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Zhimei LiuRobert W Dubois
Oct 27, 2007·Haemophilia : the Official Journal of the World Federation of Hemophilia·M ShankarR A Kadir
Mar 28, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ian S FraserAndrea S Lukes
Jul 19, 2008·Fertility and Sterility·Kristen A MattesonMelissa A Clark
Sep 23, 2010·Obstetrics and Gynecology·Andrea S LukesGary A Shangold
Oct 15, 2010·Current Medical Research and Opinion·Andrea S LukesDonald L Patrick

❮ Previous
Next ❯


Nov 3, 2012·Archives of Gynecology and Obstetrics·Hatem Abu Hashim
Apr 19, 2013·Archives of Gynecology and Obstetrics·Azita GoshtasebiSamira Behboudi Gandevani
Nov 28, 2012·Reviews in Endocrine & Metabolic Disorders·Joanna Davies, Rezan A Kadir
Sep 8, 2012·International Journal of Women's Health·Henri Leminen, Ritva Hurskainen
Jul 1, 2014·Maturitas·Faustino R Pérez-LópezMargaret Rees
Sep 1, 2012·Women's Health·Andrea S LukesTammie L Adomako
Jul 28, 2012·Current Medical Research and Opinion·Kenneth E Fox
Jan 7, 2015·Thrombosis Research·Lilian TengbornErik Berntorp
Aug 21, 2012·Nursing for Women's Health·Jeanne M Wilton
Aug 10, 2015·American Journal of Obstetrics and Gynecology·Linda D Bradley, Ndeye-Aicha Gueye
May 23, 2016·Thrombosis Research·Ayesha Zia, Madhvi Rajpurkar
Jul 20, 2012·The Annals of Pharmacotherapy·Sandra L Hrometz
Apr 16, 2018·The Cochrane Database of Systematic Reviews·Alison C Bryant-SmithMartha Hickey
May 3, 2013·Obstetrics and Gynecology·Kristen A MattesonUNKNOWN Society of Gynecologic Surgeons Systematic Review Group
Dec 4, 2016·Hematology·Andra H James
Jan 5, 2021·Frontiers in Physiology·Giris JacobBenjamin Brenner
Jun 15, 2021·EClinicalMedicine·Amani MeaidiOejvind Lidegaard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.